Wells Fargo
NVCR icon

Wells Fargo’s NovoCure NVCR Stock Holding History

Wells Fargo’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,000
Closed -$367K – 7761
2022
Q4 		$367K Buy
+5,000
New +$376K ﹤0.01% 3837

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's NVCR Position: Q1 2026 in Review

Wells Fargo increased its NovoCure (NVCR) stake by 1,996% in Q1 2026, buying an estimated $35.1M and bringing the position to 2,951,237 shares worth $32.2M. The position accounts for 0.01% of the portfolio, ranked #1215.

Wells Fargo first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $197M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Wells Fargo held 2,951,237 shares of NovoCure worth $32.2M as of Q1 2026.
  • Wells Fargo bought 2,810,424 NovoCure shares in Q1 2026, an estimated $35.1M.
  • NovoCure made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #1215 holding.
  • Wells Fargo first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
  • Wells Fargo's NovoCure position peaked at $197M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.